Hoba Therapeutics

Biotech & Life Sciences · Copenhagen, Denmark · Founded 2016

Developer of neuropathic pain and CNS therapies. The company develops biopharmaceuticals for chronic pain and hearing loss MoreLess

Developer of medical therapeutics designed to assist neuropathic pain and CNS disorders treatments. The company specializes to develop novel biopharmaceuticals for the relief, prevention, and treatment of chronic pain and hearing loss and advancing a novel therapeutic protein targeting the cells, enabling medical practitioners with innovative effective, safe, and disease-modifying treatments for patients living with neuropathic pain. Keywords: Pharmaceuticals and Biotechnology, Bio Treatment, Nervous System, Neuropathic Pain Drugs, Pharmaceutical, Postherpetic Neuralgia, Systemic Illness, Therapeutic Protein.

Valuation $100–500M

Headcount <100

Total funding $10–50M

Unlock exact values

Company overview

Hoba Therapeutics company information

The essential company record, classifications and operating signals in one place.

Status: Operational
Founded: 2016
Headquarters: Copenhagen, Denmark
Employees: 5
Open positions: None listed
Dealroom signal: 58.4

Website ↗LinkedIn ↗X ↗

client focusb2bsub industryBioTechnologybusiness modelManufacturingsectorInnovation ManagementindustryHealthsectorDeveloper ToolssectorBiotechnologysectorEICsectorBiotech and PharmasectorEIC FundsectorHard TechsectorHorizon EuropesectorproteomicssectorDT and LS

Valuation & funding

Hoba Therapeutics funding history

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	Dec 2023	$25M	$101M	Export and Investment Fund of Denmark · Novo Holdings · EIC Fund · Eir Ventures	↗
EARLY VC✓Equity / VC	Oct 2021	$0	—	EIC Fund	—
GRANT✓Other financing	Jun 2021	$2.3M	—	European Innovation Council	—
EARLY VC✓Equity / VC	Jun 2021	$0	—	EIC Fund	—

Showing 4 recorded eventsUnlock the complete deal history →

Financials

Revenue, earnings and profit over time

Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.

Year	Profit	Margin
2026	−$4.1M	—
2025	−$4.1M	—
2024	−$4.1M	—
2023
2022
2021
2020

Company filings, research estimates and Dealroom dataOpen the full financial model →

Growth signals

Hoba Therapeutics website traffic

Latest recorded traffic for Hoba Therapeutics is 270 monthly website visits, down 35.7% over the last three months. Hoba Therapeutics's team declined 54.5% over the past year.

Latest monthly visits270 3-month web change-35.7% 1-year team growth-54.5%

Monthly website visits54 observations · Dec 2018–Jul 2026

Hover or focus a point to see its exact monthly valueCompare with peers →

Comparisons

Hoba Therapeutics compared with similar companies

Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
HPHerantis PharmaInnovative biotech company developing disease modifying therapies for Parkinson’s disease	Helsinki, Finland	Operational	24	$18M	$28M
PEPeptomycFoundational anti-MYC mini-proteins for cancer treatment	Barcelona, Spain	Operational
SESentanteDeveloping a radiation-reducing manipulator and a minimally invasive coronary robotic system for endovascular procedures	Kaunas, Lithuania	Operational
PTPROSION TherapeuticsPROSION Therapeutics is a drug development company with a proprietary platform that addresses highly unmet medical needs by unlocking undruggables	Cologne, Germany	Operational
AAAlginor ASAAlginor's green innovation, AORTA, increases the utilisation ratio of seaweeds from approximately 15 to 100% without using formaldehyde and other harmful chemicals	Haugesund, Norway	Operational
OSOsivaxA company developing "universal" vaccines able to prevent highly-mutating respiratory viral infections	Lyon, France	Operational
IBInterAx BiotechDelivering High-Quality Drug Candidates for GPCR Targets	Villigen, Switzerland	Operational
IPIlya PharmaIlya Pharma develops immune-cell therapies. The company's biological medicine uses lactic acid bacteria as vectors to deliver biological drugs on-site to skin wounds or the GI tract	Uppsala kommun, Sweden	Operational

Showing 8 of the closest matchesCompare every metric →

Talent graph

Hoba Therapeutics's talent

Book a demo to see the people

Team profiled 11 named & role-tagged

Founders /100 quality score

Key operators 3 quality /100

Potential founders likely future founders

Startup mafia alumni-founded startups

Talent movements in · out past 12 months

Source: Dealroom Talent Intelligence.

Investors

9 investors on Hoba Therapeutics's cap table

Sourced from Dealroom's funding and investor records.

Seed 1 investor entered at this stage

European Innovation Council

Series A 6 investors entered at this stage

EIC Fund

Indaco Venture Partners

Medical Incubator Japan

Export and Investment Fund of Denmark

Novo Holdings

Eir Ventures

Other known 2 additional known investors

Borean Innovation

Novo Ventures

Global footprint

Where Hoba Therapeutics has talent and traffic

Workforce by country

3 countries with
team presence

🇩🇰 Denmark60%

🇧🇪 Belgium20%

🇵🇹 Portugal20%

3 countries shown

In the news

Latest news about Hoba Therapeutics

Recent press, funding announcements, and product moves mentioning Hoba Therapeutics — open to read from the original sources.

See all news

Market sentiment

What the market is saying about Hoba Therapeutics

An AI-synthesized read of the highest-engagement posts about Hoba Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Hoba Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Request a free trial

Takes under a minute. Already use Dealroom? Log in.